以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 肥胖世界 Obesity World 《肥胖世界》(Obesity World)关注电子杂 志官方账号,用前沿科学理解肥胖 www.obesityworld.cn Obesity World 用 前 沿 科 学 理 解 肥 胖 研究背景与目的 背景：全球肥胖发生率不断攀升，氨基酸限量膳食作为一种潜在干预方法日益受到重视。半胱氨酸是合成谷胱甘肽（GSH）和辅酶A（CoA） 的重要前体，但仅限制半胱氨酸对体重的具体影响及其调控机制仍不明朗。 目的：本研究利用小鼠实验，探讨半胱氨酸限制引发快速体重降低的分子机制，为肥胖治疗提供全新靶点。 研究方法 研究设计：本研究选用Cse基因敲除（KO）和野生型（WT）小鼠，分别给予半胱氨酸剔除膳食（no-Cys）及其他必需氨基酸限制膳食，结合 代谢笼监测、转录组与代谢组学综合分析。 数据来源：主要采集小鼠肝脏、肌肉、脂肪组织， ...

PresentationGood morning, and welcome to the Arrowhead Pharmaceuticals' Virtual KOL event. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be available on the Arrowhead website following the event.Vincent AnzaloneHead of Investor Relations & VP Thanks so much, Wilson, and thanks, everybody, for joining us today. We are excited to talk about our first interim results from our 2 obesity candidates, ARO-INHBE and ARO-ALK7. The press release went out this morning. So I'd l ...

Core Viewpoint - Mazdutide, developed by Innovent Biologics, is a dual receptor agonist targeting GCG and GLP-1, showing promising results in weight loss and liver fat metabolism improvement for obese and overweight adults in China [1][2]. Group 1: Clinical Trial Results - The Phase 3 clinical trial GLORY-1 published in NEJM demonstrated that weekly injections of Mazdutide resulted in significant weight loss and safety in obese or overweight Chinese adults [1]. - In the trial, participants receiving Mazdutide showed a reduction in HbA1c of 1.57% for the 4 mg group and 2.15% for the 6 mg group, compared to a 0.14% reduction in the placebo group [5]. - The weight loss observed was 5.61% for the 4 mg group and 7.81% for the 6 mg group, while the placebo group lost only 1.26% [5]. Group 2: Regulatory Approval - Based on the successful clinical trial results, the National Medical Products Administration (NMPA) approved Mazdutide for long-term weight management in adults with obesity or overweight on June 27, 2025 [2]. Group 3: Additional Research Findings - Two additional Phase 3 studies on Mazdutide for treating type 2 diabetes were published back-to-back in Nature, marking a significant achievement for Chinese drug development in the metabolic and endocrine disease field [2][10]. - In a separate study comparing Mazdutide to Dulaglutide, both doses of Mazdutide showed non-inferiority and superiority in reducing HbA1c compared to Dulaglutide, with treatment differences of -0.24% and -0.30% respectively [9]. - The weight loss was significantly greater in the Mazdutide groups, with differences of -3.78% for the 4 mg group and -5.76% for the 6 mg group compared to Dulaglutide [9].

Welcome back. Novo Nordisk gaining FDA approval for the first oral weight loss drug. Our Anakah Constantino spoke with the CEO and joins us this morning.Hey, Anakah. >> Hi, Carl. That's right.So, we're all familiar with Novo's Blockbuster Weekly injection, Mgoi. But for the very first time, patients will be able to access an oral version of that drug. It's the first ever GLP-1 pill specifically approved for obesity, and it's launching early in 2026.And Novo says it's priced at a significant discount to what ...

考虑到GLP-1疗法的效果，世卫组织将之形容为具有里程碑意义的政策变革。"GLP-1疗法不仅是一项科 学突破，更标志着社会对肥胖症认知转变的新篇章——从一种生活方式疾病转变为一种复杂、可预防、 可治疗的慢性疾病。"世界卫生组织肥胖问题高级顾问Francesca Celletti撰文说。 世界卫生组织在最新发布的一份指南中明确，GLP-1类药物可用于成年人的长期肥胖治疗（孕妇除 外）。受评估的药物包括利拉鲁肽、司美格鲁肽、替泽帕肽等热门品种。虽然明确了药物的效果，指南 仍然强调，只靠药物本身无法根本解决肥胖问题，社会层面还需要营造更健康的环境，包括对含糖饮料 等不健康食品征税、限制不健康食品的营销和并降低其可及性、改良食品配方，以及实施食品包装正面 标识等。 近年来以GLP-1类药物为代表的减重药品大火，其通过抑制食欲、减少胃排空等，降低能量摄入进而起 到控制乃至减重的效果。在火爆同时，业内也担心公众滥用药物，进而引发其他健康风险。世卫组织在 本月初发布的指南，通过评估一批最新的研究证据，给出了政策建议。 指南明确，以利拉鲁肽、司美格鲁肽、替泽帕肽等为代表的GLP-1类药物和GLP-1/GIP双受体激动剂， 可 ...

指南表示，GLP-1类药物是首个对肥胖成人有效的治疗选择，但药物本身无法根本解决肥胖问题。肥胖 不仅是个人问题，更是全社会的挑战，需要多部门协作。综合策略应包括，制定有力的群体性政策，营 造更健康的环境（包括对含糖饮料等不健康食品征税、限制不健康食品的营销并降低其可及性、改良食 品配方，以及实施食品包装正面标识等），预防肥胖；针对高风险人群开展筛查和早期干预；确保获得 终身、以人为本的护理服务。 在中国，随着居民生活水平提升，肥胖症日益成为威胁公众健康的重大因素。根据国家卫生健康委《肥 胖症诊疗指南（2024年版）》数据显示，中国成年人超重率已达34.3%，肥胖率为16.4%。 对GLP-1药物提出有条件推荐。 GLP-1（胰高血糖素样肽-1）类药物成为肥胖治疗的"黑科技"，但如何规范化使用，仍需要引起重视。 近日，世界卫生组织发布了首个关于将GLP-1类药物用于治疗肥胖——这一慢性、易复发的疾病的指 南。 肥胖是一种复杂的慢性疾病，是心血管疾病、2型糖尿病及部分癌症等非传染性疾病的重要诱因，也会 加重传染性疾病患者的病情。世界卫生组织预计全球因肥胖带来的经济负担到2030年将达3万亿美元。 此次指南对GLP ...

世卫组织将成人体重指数（BMI）≥30定义为肥胖。GLP-1受体激动剂是一类可降低血糖、帮助减重、 降低心肾并发症风险，并可降低2型糖尿病患者早亡风险的药物。值得关注的是，本次指南所提及的 GLP-1类药物中，包含了近年来备受全球医学界与资本市场关注的分子——司美格鲁肽。 为应对全球日益严峻的肥胖健康挑战，近日，世界卫生组织发布了首个关于将胰高血糖素样肽-1 （GLP-1）类药物用于治疗肥胖的全球指南。 肥胖症是一种慢性复发性疾病，据联合国新闻官网消息，目前，全球已有超过10亿人受肥胖困扰。2024 年肥胖相关死亡人数高达370万。若不采取果断行动，预计到2030年，肥胖人数还将翻倍。 世卫组织总干事谭德塞博士表示："肥胖是全球重大健康挑战，世卫组织致力于支持各国和全球人民有 效、公平地应对。新指南承认肥胖是一种可通过综合、终身护理治疗的慢性疾病。虽然药物本身无法解 决全球健康危机，但GLP-1类药物可帮助数百万人克服肥胖，减少相关危害。" 肥胖是一种复杂的慢性疾病，是心血管疾病、2型糖尿病及部分癌症等非传染性疾病的重要诱因，也会 加重传染性疾病患者的病情。新指南有助于降低因肥胖及其并发症带来的医疗成本。包括 ...

Core Insights - The article discusses the revolutionary impact of GLP-1 receptor agonists, particularly semaglutide, in the treatment of obesity and related metabolic disorders, highlighting their effectiveness in appetite suppression and calorie intake reduction [6] - A new oral candidate drug, ATR-258, shows promising results in preclinical studies, demonstrating similar glucose control and weight loss effects as GLP-1 injections without the common side effects associated with GLP-1 drugs [7][9] - ATR-258 is designed to selectively activate β2 adrenergic receptors, enhancing muscle metabolism while minimizing cardiac side effects, representing a significant advancement in obesity and type 2 diabetes treatment options [11][12] Group 1: GLP-1 Receptor Agonists - GLP-1 receptor agonists, such as semaglutide, require weekly injections and are effective in treating obesity, type 2 diabetes, cardiovascular diseases, and sleep apnea [6] - These drugs have transformed obesity treatment by effectively suppressing appetite and reducing caloric intake [6] Group 2: ATR-258 Development - ATR-258, a β2 adrenergic receptor partial agonist, has shown excellent pharmacokinetics and tolerability in phase 1 clinical trials involving healthy volunteers and type 2 diabetes patients [9] - The drug aims to achieve "healthy weight loss" by reducing fat without losing muscle mass, which is crucial for patients with type 2 diabetes and obesity [11] - Atrogi AB plans to conduct larger phase 2 clinical trials to validate the positive effects observed in animal models for type 2 diabetes and obesity patients [12]

Core Insights - Novo Nordisk announced clinical trial data for its new diabetes drug amycretin, demonstrating significant weight loss effects alongside blood sugar reduction [2] Group 1: Clinical Trial Results - The trial results indicate that the amycretin injection, administered once weekly, can help patients lose up to 14.5% of their body weight over 36 weeks [2] - The daily oral formulation of amycretin can achieve a weight loss of up to 10.1% [2] Group 2: Market Impact - This positive news led to a rise in Novo Nordisk's stock price in the US, recovering much of the losses incurred from the underperformance of its Ozempic oral version in two Alzheimer's clinical trials [2] Group 3: Strategic Importance - Amycretin is a key component of Novo Nordisk's new generation of drug combinations, integrating two weight loss mechanisms into a single molecule, aimed at enhancing the company's competitive position in the obesity treatment market [2]

Core Viewpoint - The application for the high-dose 9mg of Xinermy (Mastideptin injection) for long-term weight control in adults with moderate to severe obesity has been accepted by the National Medical Products Administration (NMPA) in China, indicating a potential new treatment option for this demographic beyond weight loss surgery [1] Group 1 - Xinermy is a dual receptor agonist for glucagon ("GCG") and glucagon-like peptide-1 ("GLP-1") [1] - The drug is expected to provide a strong and safe treatment alternative for the moderately to severely obese population in China [1]